# Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

> **NCT03700905** · PHASE3 · UNKNOWN · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 276 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **PROCEDURE:** Surgical resection of primary tumor
- **RADIATION:** Adjuvant radio(-chemo)therapy
- **DRUG:** Neoadjuvant Nivolumab
- **DRUG:** Adjuvant Nivolumab
- **DRUG:** Adjuvant Nivolumab and Ipilimumab

## Key facts

- **NCT ID:** NCT03700905
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-21
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2023-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03700905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03700905, "Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03700905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*